PPARA and metabolic dysfunction-associated steatotic liver disease: PPARα activation is known to improve steatosis and inflammation in pre-clinical models of NAFLD, whereas mice lacking hepatocytic PPARα develop hepatic steatosis and patients with NAFLD display reduced expression of PPARα23,36.